demethylases

GSK-J4 (GSK J4 HCl) is a cell permeable prodrug of GSK-J1, a dual inhibitor of the H3K27me3 me2 demethylases JMJD3 KDM6B and UTX KDM6A (IC50=8.6 6.6 μM). GSK-J4 induces endoplasmic reticulum stress-related apoptosis.

Daminozide (Succinic Acid) is a plant growth regulator, selectively inhibits the KDM2 7 JmjC subfamily.

IOX1 is the most effective broad-spectrum 2OG oxygenases(including the JmjC demethylases) inhibitor. The IC50 of IOX1 for KDM4A, KDM3A, is 0.6 and 0.1 uM, respectively.

(Z)-JIB-04 (NSC 693627) is an isomer of JIB-04.

KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells. KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor

L-2-Hydroxyglutaric acid disodium ((S)-2-Hydroxyglutaric acid disodium) is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity(Km and Ki of 2.52 mM and 11.13 mM, respectively).

lutidinic acid (2,4-Dicarboxypyridine) is an in vitro and in cell inhibitor, as well as a known inhibitor of the histone lysine demethylases.

GSK-J1 lithium salt is an effective inhibitor of H3K27me3 me2-demethylases JMJD3 KDM6B and UTX KDM6A, with an IC 50 of 60 nM for KDM6B.

GSK-J1 sodium salt is a potent inhibitor of the H3K27 histone demethylases JMJD3 and UTX.

KDM5-C49 (KDOAM-20) hydrochloride is a potent, selective inhibitor of the KDM5 family of demethylases, with IC50 values of 40 nM for KDM5A, 160 nM for KDM5B, and 100 nM for KDM5C. This compound is utilized in cancer research [1].

KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor, with IC50 values of 71 nM, 19 nM, 69 nM, and 69 nM for KDM5A, KDM5B, KDM5C, and KDM5D, respectively. Multiple myeloma MM1S cells treated with KDOAM-25 citrate show increased global H3K4 methylation at transcriptional start sites and impaired proliferation [1].

CP2 is a useful organic compound for research related to life sciences and the catalog number is T35338.

SDZ-285604 is a novel sterol 14a-demethylases (CYP51) inhibitor.

KDOAM-25, a potent and highly selective inhibitor of histone lysine demethylases 5 (KDM5) with IC50 values of 71 nM for KDM5A, 19 nM for KDM5B, 69 nM for KDM5C, and 69 nM for KDM5D, enhances global H3K4 methylation at transcriptional start sites and reduces proliferation in multiple myeloma MM1S cells.

CPI-4203 is a selective inhibitor of KDM5 demethylases.

GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.

GSK-J2 sodium, the sodium form of GSK-J2, is an isomer of GSK-J1 and lacks specific activity. GSK-J1 is a potent inhibitor of H3K27me3 me2-demethylases JMJD3 KDM6B and UTX KDM6A [1].

L-2-Hydroxyglutaric acid (L-2-HG) is a compartmentalized metabolite and a substrate for L-2-hydroxyglutarate dehydrogenase (L2HGDH). It inhibits histone demethylases and increases the expression of ATF4 and its target genes by activating the mTOR pathway. L-2-Hydroxyglutaric acid mediates the mTOR-ATF4 signaling pathway and can be used in biosensor research.

DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.